Viral Load Predicts New World Health Organization Stage 3 and 4 Events in HIV‐Infected Children Receiving Highly Active Antiretroviral Therapy, Independent of CD4 T Lymphocyte Value
Open Access
- 1 December 2010
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 51 (11), 1325-1333
- https://doi.org/10.1086/657119
Abstract
Background. Many resource-limited countries rely on clinical and immunological monitoring without routine virological monitoring for human immunodeficiency virus (HIV)-infected children receiving highly active antiretroviral therapy (HAART). We assessed whether HIV load had independent predictive value in the presence of immunological and clinical data for the occurrence of new World Health Organization (WHO) stage 3 or 4 events (hereafter, WHO events) among HIV-infected children receiving HAART in Latin America. Methods. The NISDI (Eunice Kennedy Shriver National Institute of Child Health and Human Development International Site Development Initiative) Pediatric Protocol is an observational cohort study designed to describe HIV-related outcomes among infected children. Eligibility criteria for this analysis included perinatal infection, age 5000 copies/mL was associated with a nearly doubled risk of developing a WHO event (adjusted hazard ratio, 1.81; 95% confidence interval, 1.05–3.11; P = .033), even after adjustment for immunological status defined on the basis of CD4 T lymphocyte value, hemoglobin level, age, and body mass index. Conclusions. Routine virological monitoring using the WHO virological failure threshold of 5000 copies/mL adds independent predictive value to immunological and clinical assessments for identification of children receiving HAART who are at risk for significant HIV-related illness. To provide optimal care, periodic virological monitoring should be considered for all settings that provide HAART to children.Keywords
This publication has 23 references indexed in Scilit:
- Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children During the HAART EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Effectiveness of Pediatric Antiretroviral Therapy in Resource‐Limited Settings: A Systematic Review and Meta‐analysisClinical Infectious Diseases, 2009
- Risk of Extended Viral Resistance in Human Immunodeficiency Virus-1-Infected Mozambican Children After First-Line Treatment FailureThe Pediatric Infectious Disease Journal, 2009
- Dried Blood Spots Perform Well in Viral Load Monitoring of Patients Who Receive Antiretroviral Treatment in Rural TanzaniaClinical Infectious Diseases, 2009
- Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2009
- Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapyAIDS, 2009
- Cohort Profile: NICHD International Site Development Initiative (NISDI): a prospective, observational study of HIV-exposed and HIV-infected children at clinical sites in Latin American and Caribbean countriesInternational Journal of Epidemiology, 2008
- A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA StudyThe Journal of Infectious Diseases, 2002
- Viral Load and Disease Progression in Infants Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1997
- The Relationship between Serum Human Immunodeficiency Virus Type 1 (HIV‐1) RNA Level, CD4 Lymphocyte Percent, and Long‐Term Mortality Risk in HIV‐1—Infected ChildrenThe Journal of Infectious Diseases, 1997